patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
3-2-16, Pluristem's Radiation Antidote Bests Blockbuster Drug Neupogen
PLX-R18 Heals 100% of Population Exposed To Lethal Radiation through Nuclear Accident or Attack; Ready To Supply U.S. Government.
2-2-15, Significant New Finding From Its Phase I/II Muscle Injury Trial - Excellent Safety Profile for Cells at Twelve Months.
Data showed the magnitude of improvement in muscle force of 40 times larger in patients treated with PLX-PAD.
3-6-14, US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process.
Pluristem Fortifies Leadership Position in Cell Therapy Following Multiple Regulatory Approvals of Its New PLX Cell Mass Production Facility.
3-2-16, Pluristem's Radiation Antidote Bests Blockbuster Drug Neupogen
PLX-R18 Heals 100% of Population Exposed To Lethal Radiation through Nuclear Accident or Attack; Ready To Supply U.S. Government.
2-2-15, Significant New Finding From Its Phase I/II Muscle Injury Trial - Excellent Safety Profile for Cells at Twelve Months.
Data showed the magnitude of improvement in muscle force of 40 times larger in patients treated with PLX-PAD.
3-6-14, US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process.
Pluristem Fortifies Leadership Position in Cell Therapy Following Multiple Regulatory Approvals of Its New PLX Cell Mass Production Facility.
1-21-14, Pluristem's Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints.
PLX-PAD Cells Show Statistically Significant Improvement Over Placebo in the Change of the Maximal Contraction Force of the Gluteal Muscle.
12-17-13, Pluristem and CHA Move Forward on Strategic Partnership Agreement; Conclude Mutual Investment of $10.4 Million.
9-11-13, Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery Disease.
Exclusive Rights to Treat PAD With Placental Cells in the U.S.
1-30-13, Pluristem Takes Possession of and Moving Into New State-of-the-Art Manufacturing Facility.
The facility allows for the production of mass quantities of PLacental eXpanded (PLX) cells that possess the advantages of being grown utilizing Pluristem's patented 3D bioreactor technology.
Sep 5, 2012, Third Critically Ill Patient Successfully Treated. Aug 2012, Life of 2nd Cancer Patient Suffering From Bone Marrow Failure Saved. May 2012, Pluristem's PLX Cells Saves the Life of a Child after Bone Marrow Transplantation Failure.
11-8-12 Pluristem comments on an article published in Bloomberg on November 7, 2012 about patient deaths.
Pluristem and United Therapeutics Enter into an Exclusive License Agreement to Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension.
United Therapeutics will make an upfront payment of $7 million to Pluristem; and other payments accumulating together with the upfront payment to a total of approximately $55 million.